Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zhenlin Ju

Showing results (61-70 of 83) with videos related to

Pageof 9
Sort By:
Nature Medicine|May 9, 2018
ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockadeJianfeng Shen, Zhenlin Ju, Wei Zhao, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 16, 2014
Pla2g16 phospholipase mediates gain-of-function activities of mutant p53Shunbin Xiong, Huolin Tu, Madhusudhan Kollareddy, et al.
Cancer Immunology Research|September 12, 2020
Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic PhenotypeAshvin R Jaiswal, Arthur J Liu, Shivanand Pudakalakatti, et al.
Science Advances|April 26, 2017
A murine preclinical syngeneic transplantation model for breast cancer precision medicineLorenzo Federico, Zechen Chong, Dong Zhang, et al.
Science Translational Medicine|June 2, 2017
Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in <i>RAS</i> mutant cancersChaoyang Sun, Yong Fang, Jun Yin, et al.
Clinical Proteomics|June 22, 2011
A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast CancersBryan T Hennessy, Yiling Lu, Ana Maria Gonzalez-Angulo, et al.
Clinical Proteomics|September 13, 2011
Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancerAna M Gonzalez-Angulo, Bryan T Hennessy, Funda Meric-Bernstam, et al.
Cancer Cell|October 7, 2015
The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human CancersLeng Han, Lixia Diao, Shuangxing Yu, et al.
Nature Communications|June 26, 2026
Personalized targeting of BCL2 family proteins overcomes acquired resistance to BRAF-MEK inhibitors in preclinical melanomaVashisht Gopal Y N, Evelyn de Groot, Kaley Loftin, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 8, 2014
Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancerVivian Wai Yan Lui, Noah D Peyser, Patrick Kwok-Shing Ng, et al.
Pageof 9

Showing results (61-70 of 83) with videos related to

Sort By:
Pageof 9
Nature Medicine|May 9, 2018
ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockadeJianfeng Shen, Zhenlin Ju, Wei Zhao, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 16, 2014
Pla2g16 phospholipase mediates gain-of-function activities of mutant p53Shunbin Xiong, Huolin Tu, Madhusudhan Kollareddy, et al.
Cancer Immunology Research|September 12, 2020
Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic PhenotypeAshvin R Jaiswal, Arthur J Liu, Shivanand Pudakalakatti, et al.
Science Advances|April 26, 2017
A murine preclinical syngeneic transplantation model for breast cancer precision medicineLorenzo Federico, Zechen Chong, Dong Zhang, et al.
Science Translational Medicine|June 2, 2017
Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in <i>RAS</i> mutant cancersChaoyang Sun, Yong Fang, Jun Yin, et al.
Clinical Proteomics|June 22, 2011
A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast CancersBryan T Hennessy, Yiling Lu, Ana Maria Gonzalez-Angulo, et al.
Clinical Proteomics|September 13, 2011
Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancerAna M Gonzalez-Angulo, Bryan T Hennessy, Funda Meric-Bernstam, et al.
Cancer Cell|October 7, 2015
The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human CancersLeng Han, Lixia Diao, Shuangxing Yu, et al.
Nature Communications|June 26, 2026
Personalized targeting of BCL2 family proteins overcomes acquired resistance to BRAF-MEK inhibitors in preclinical melanomaVashisht Gopal Y N, Evelyn de Groot, Kaley Loftin, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 8, 2014
Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancerVivian Wai Yan Lui, Noah D Peyser, Patrick Kwok-Shing Ng, et al.
Pageof 9